On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback